Antigens and Antibodies of the Antiphospholipid Syndrome As New Allies in the Pathogenesis of COVID-19 Coagulopathy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 May 14

PMID 35563337

Authors

Manuel Serrano

Gerard Espinosa

Antonio Serrano

Ricard Cervera

Affiliations

Soon will be listed here.

Abstract

High prevalence of both criteria and extra-criteria antiphospholipid antibodies (aPL) has been reported in COVID-19 patients. However, the differences in aPL prevalence decreased when an age-matched control group was included. The association of aPL with thrombotic events in COVID-19 is very heterogeneous. This could be influenced by the fact that most of the studies carried out were conducted on small populations enriched with elderly patients in which aPL was measured only at a single point and they were performed with non-standardized assays. The few studies that confirmed aPL in a second measurement showed that aPL levels hardly changed, with the exception of the lupus anticoagulant that commonly reduced. COVID-19 coagulopathy is an aPL-independent phenomenon closely associated with the onset of the disease. Thrombosis occurs later in patients with aPL presence, which is likely an additional prothrombotic factor. B2-glycoprotein deficiency (mainly aPL antigen caused both by low production and consumption) is very common during the SARS-CoV2 infection and has been associated with a greater predisposition to COVID-19 complications. This could be a new prothrombotic mechanism that may be caused by the blockage of its physiological functions, the anticoagulant state being the most important.

Citing Articles

Autoantibodies in COVID-19: implications for disease severity and clinical outcomes.

Galipeau Y, Cooper C, Langlois M Front Immunol. 2025; 15():1509289.

PMID: 39835117 PMC: 11743527. DOI: 10.3389/fimmu.2024.1509289.

Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health.

Fekete M, Lehoczki A, Szappanos A, Toth A, Mahdi M, Sotonyi P Geroscience. 2025; 47(1):745-779.

PMID: 39777702 PMC: 11872997. DOI: 10.1007/s11357-024-01487-4.

The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management.

Becker R, Tantry U, Khan M, Gurbel P J Thromb Thrombolysis. 2024; 58(1):15-49.

PMID: 39179952 PMC: 11762605. DOI: 10.1007/s11239-024-03028-4.

Thrombosis and Hyperinflammation in COVID-19 Acute Phase Are Related to Anti-Phosphatidylserine and Anti-Phosphatidylinositol Antibody Positivity.

Alijotas-Reig J, Anunciacion-Llunell A, Morales-Perez S, Trape J, Esteve-Valverde E, Miro-Mur F Biomedicines. 2023; 11(8).

PMID: 37626797 PMC: 10452204. DOI: 10.3390/biomedicines11082301.

Oligosymptomatic infection by SARS-Cov-2 in catastrophic antiphospholipid syndrome, a singular coincidence: a case report in an Ecuadorian hospital.

Velez-Paez J, Carranza-Jara J, Almeida-Posso D, Witkin S, de Almeida-Neto C Hematol Transfus Cell Ther. 2023; 46(3):316-320.

PMID: 37455218 PMC: 11221254. DOI: 10.1016/j.htct.2023.06.002.

References

Matsuura E, Shen L, Matsunami Y, Quan N, Makarova M, Geske F . Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus. 2010; 19(4):379-84. DOI: 10.1177/0961203310361352. View

Klok F, Kruip M, van der Meer N, Arbous M, Gommers D, Kant K . Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020; 191:148-150. PMC: 7192101. DOI: 10.1016/j.thromres.2020.04.041. View

Sciascia S, Amigo M, Roccatello D, Khamashta M . Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. Nat Rev Rheumatol. 2017; 13(9):548-560. DOI: 10.1038/nrrheum.2017.124. View

Levi M, Thachil J, Iba T, Levy J . Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020; 7(6):e438-e440. PMC: 7213964. DOI: 10.1016/S2352-3026(20)30145-9. View

Ferrari E, Sartre B, Squara F, Contenti J, Occelli C, Lemoel F . High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019. J Am Heart Assoc. 2020; 9(21):e017773. PMC: 7763401. DOI: 10.1161/JAHA.120.017773. View

Siguret V, Voicu S, Neuwirth M, Delrue M, Gayat E, Stepanian A . Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?. Thromb Res. 2020; 195:74-76. PMC: 7342042. DOI: 10.1016/j.thromres.2020.07.016. View

Xiao M, Zhang Y, Zhang S, Qin X, Xia P, Cao W . Antiphospholipid Antibodies in Critically Ill Patients With COVID-19. Arthritis Rheumatol. 2020; 72(12):1998-2004. PMC: 7361932. DOI: 10.1002/art.41425. View

Fields R, Toubbeh H, Searles R, Bankhurst A . The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol. 1989; 16(5):623-5. View

Kolialexi A, Tsangaris G, Sifakis S, Gourgiotis D, Katsafadou A, Lykoudi A . Plasma biomarkers for the identification of women at risk for early-onset preeclampsia. Expert Rev Proteomics. 2017; 14(3):269-276. DOI: 10.1080/14789450.2017.1291345. View

10.

Brighton T, Hogg P, Dai Y, Murray B, Chong B, Chesterman C . Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol. 1996; 93(1):185-94. DOI: 10.1046/j.1365-2141.1996.446981.x. View

11.

Sene D, Piette J, Cacoub P . [Antiphospholipid antibodies, antiphospholipid syndrome and viral infections]. Rev Med Interne. 2008; 30(2):135-41. DOI: 10.1016/j.revmed.2008.05.020. View

12.

Mendoza-Pinto C, Garcia-Carrasco M, Cervera R . Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant). Curr Rheumatol Rep. 2018; 20(10):62. DOI: 10.1007/s11926-018-0773-x. View

13.

Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart D . Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med. 2020; 383(3):288-290. PMC: 7217555. DOI: 10.1056/NEJMc2013656. View

14.

Meroni P, Borghi M, Grossi C, Chighizola C, Durigutto P, Tedesco F . Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nat Rev Rheumatol. 2018; 14(7):433-440. DOI: 10.1038/s41584-018-0032-6. View

15.

Trahtemberg U, Rottapel R, Santos C, Slutsky A, Baker A, Fritzler M . Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Ann Rheum Dis. 2021; 80(9):1236-1240. PMC: 8076626. DOI: 10.1136/annrheumdis-2021-220206. View

16.

Morales J, Serrano M, Martinez-Flores J, Perez D, Castro M, Sanchez E . The Presence of Pretransplant Antiphospholipid Antibodies IgA Anti-β-2-Glycoprotein I as a Predictor of Graft Thrombosis After Renal Transplantation. Transplantation. 2016; 101(3):597-607. DOI: 10.1097/TP.0000000000001199. View

17.

Middleton E, He X, Denorme F, Campbell R, Ng D, Salvatore S . Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020; 136(10):1169-1179. PMC: 7472714. DOI: 10.1182/blood.2020007008. View

18.

Mendoza-Pinto C, Escarcega R, Garcia-Carrasco M, Bailey D, Galvez-Romero J, Cervera R . Viral infections and their relationship with catastrophic antiphospholipid syndrome: a possible pathogenic mechanism of severe COVID-19 thrombotic complications. J Intern Med. 2020; 288(6):737-739. PMC: 7300456. DOI: 10.1111/joim.13123. View

19.

McDonnell T, Wincup C, Buchholz I, Pericleous C, Giles I, Ripoll V . The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev. 2019; 39:100610. PMC: 7014586. DOI: 10.1016/j.blre.2019.100610. View

20.

Previtali G, Seghezzi M, Moioli V, Sonzogni A, Cerutti L, Marozzi R . The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?. Thromb Res. 2020; 194:192-194. PMC: 7319923. DOI: 10.1016/j.thromres.2020.06.042. View